6533b7d1fe1ef96bd125c387

RESEARCH PRODUCT

Effects of age and gender in patients receiving doses of opioids for breakthrough pain proportional to background opioid doses.

Alessandra CasuccioVincenzo RestivoSebastiano Mercadante

subject

MalePain medicineAnalgesicFentanyl03 medical and health sciencesBasal (phylogenetics)Age0302 clinical medicinemedicineHumans030212 general & internal medicineCancer painAdverse effectAgedPain Measurementbusiness.industryBreakthrough PainAge FactorsGenderGender IdentityFentanylAnalgesics OpioidRegimenTreatment OutcomeOncologyOpioid030220 oncology & carcinogenesisAnesthesiaFemaleCancer painbusinessmedicine.drug

description

Aim: To identify the role of age and gender in analgesic and adverse effects after administering fentanyl products for breakthrough pain (BT), given in doses proportional to opioid doses given for background pain. Methods: Data from nine studies, in which patients with BP were given fentanyl products in doses proportional to their basal opioid regimen, were analyzed. Results: A total 462 patients presenting 1905 episodes of BP were included in this analysis. In older patients, the decrease in pain intensity was more pronounced 15 min after administration of a BP medication. No gender differences were found. No significant differences in frequency and intensity of adverse effects for age and gender were found. Conclusion: Fentanyl products given for BP in doses proportional to background opioid regimen were more effective in older patients without adding risks of adverse effects. Gender did not influence analgesia and adverse effects of fentanyl products.

10.1007/s00520-019-05227-9https://pubmed.ncbi.nlm.nih.gov/31832823